Anthera Pharmaceuticals, Inc.
ANTH · OTC
3/31/2018 | 12/31/2017 | 9/30/2017 | 6/30/2017 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $7 | $8 | $6 | $7 |
| Gross Profit | -$7 | -$8 | -$6 | -$7 |
| % Margin | – | – | – | – |
| R&D Expenses | $7,468 | $7,655 | $6,104 | $7,034 |
| G&A Expenses | $3,503 | $1,600 | $1,810 | $1,625 |
| SG&A Expenses | $3,503 | $1,600 | $1,810 | $1,625 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$43 | $0 | $0 | $0 |
| Operating Expenses | $10,971 | $9,255 | $7,914 | $8,659 |
| Operating Income | -$10,971 | -$9,255 | -$7,914 | -$8,659 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,247 | -$418 | $1,607 | $8,972 |
| Pre-Tax Income | -$7,724 | -$9,673 | -$6,307 | $313 |
| Tax Expense | -$3,290 | $383 | -$1,648 | -$8,972 |
| Net Income | -$4,434 | -$10,056 | -$4,659 | $9,285 |
| % Margin | – | – | – | – |
| EPS | -0.2 | -0.76 | -0.43 | 0.92 |
| % Growth | 73.7% | -76.7% | -146.7% | – |
| EPS Diluted | -0.2 | -0.76 | -0.43 | 0.92 |
| Weighted Avg Shares Out | 22,167 | 13,191 | 10,947 | 10,136 |
| Weighted Avg Shares Out Dil | 22,167 | 13,191 | 10,947 | 10,136 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$3,129 | $418 | -$1,607 | -$8,812 |
| EBITDA | -$10,810 | -$9,220 | -$7,873 | -$8,499 |
| % Margin | – | – | – | – |